4-PBA sodium; Sodium 4-phenylbutyrate; Sodium phenylbutyrate; 4-phenylbutyrate (4-PBA); 4-phenylbutyric acid; Buphenyl
Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Sodium phenylbutyrate (4-Phenylbutyric acid sodium; 4-PBA sodium), an orphan drug marketed by Ucyclyd Pharma, is a novel and potent histone deacetylase (HDAC) inhibitor used as an as adjunctive therapy for chronic treatment of urea cycle disorders involving deficiencies of argininosuccinic acid synthetase (AS), ornithine transcarbamylase (OTC), or carbamylphosphate synthetase (CPS). Because metabolites of sodium phenylbutyrate offer an alternative pathway to the urea cycle for the excretion of excess nitrogen. It has strong anti-cancer properties as well.
Targets |
HDAC
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
In brief, viable cells are seeded at a density of 4 × 104 cells/mL in 60-mm dishes in RPMI 1640 with 10% fetal bovine serum and 0.35% agarose on a base layer of 0.7% agarose. Viable cells are determined by trypan blue dye exclusion. Additions of DMSO, TSA, or PB are made to the upper and lower agarose layers. Colonies are counted after 10–14 days, and assays are run in triplicate at least three times.
|
|
Animal Protocol |
|
|
References |
Molecular Formula |
C10H11O2.NA
|
|
---|---|---|
Molecular Weight |
186.18
|
|
Exact Mass |
186.07
|
|
Elemental Analysis |
C, 64.51; H, 5.96; Na, 12.35; O, 17.19
|
|
CAS # |
1716-12-7
|
|
Related CAS # |
|
|
Appearance |
Solid powder
|
|
SMILES |
C1=CC=C(C=C1)CCCC(=O)[O-].[Na+]
|
|
InChi Key |
VPZRWNZGLKXFOE-UHFFFAOYSA-M
|
|
InChi Code |
InChI=1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
|
|
Chemical Name |
sodium;4-phenylbutanoate
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (537.11 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.3711 mL | 26.8557 mL | 53.7115 mL | |
5 mM | 1.0742 mL | 5.3711 mL | 10.7423 mL | |
10 mM | 0.5371 mL | 2.6856 mL | 5.3711 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT06069375 | Recruiting | Drug: Sodium phenylbutyrate | Medium-chain Acyl-CoA Dehydrogenase Deficiency |
Jerry Vockley, MD, PhD | December 2023 | Phase 2 |
NCT02111200 | Completed | Drug: Sodium Phenylbutyrate Drug: Sodium Benzoate |
Urea Cycle Disorders, Inborn | Baylor College of Medicine | September 2014 | Not Applicable |
NCT01529060 | Completed | Drug: Phenylbutyrate Drug: Placebo powder |
Maple Syrup Urine Disease | Brendan Lee | February 2013 | Phase 2 Phase 3 |
NCT00107770 | Completed | Drug: sodium phenylbutyrate | Amyotrophic Lateral Sclerosis | US Department of Veterans Affairs |
April 2005 | Phase 1 Phase 2 |